Get started
Artelo Biosciences, Inc.Artelo Biosciences, Inc.Artelo Biosciences, Inc.

Artelo Biosciences, Inc.

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonals

Trade ideas

tradingview is a bitch making me re-write all this shitIndications & Patterns Monthly TF - Descending Wedge formed and being tested - EMA21 being tested with ATH volume Weekly TF - Heavily tested EMA21 and SMA50 broken and have crossed - SMA100 now being tested - Leaplong downtrend line forming descending triangle with fib 0 - Bullish Div on Sqzmom Daily TF - Bear div w/ possible hidden bull div on MacZ - SMA200 crossed EMA21, SMA50 and now close to SMA100 2hr TF - EMA21 transitioning to downtrend Fundamentals - Medical Cannabis Sector (Biden) - Sector leaders such as AXIM,ZYNE,OWCP have increased 100%+ since Feb, but before the recent red days. ARTL has lower market cap then them, they have increased 200%+ since Feb - "Authorized Shares of Common Stock from 18,750,000 to 750,000,000." Dec.12 - "Equity Incentive plan from 2018 recently passed by SEC" Dec.16 - Share Float - 45% - 37% held by investors, 18% by shareholders - Short volume .20 - Short float - 14% Verdict - Sideways, or even downtrend for the coming weeks, followed by a pump to $6.5 area to fill gap down
NASDAQ:ARTL
by TBirben
$ARTL surged 92% on buy rating from Ladenburg analystArtelo Biosciences surged 92% on buy initiation from Ladenburg Shares of $ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating. They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday. Ladenburg analyst cites Artelo's focus on candidates targeting the endocannabinoid system. Artelo Biosciences is a biopharma company focused on developing treatments that improve patients’ lives. That includes developing new therapies. The company’s pipeline includes ART27.13, which is designed to treat cancer patients suffering from anorexia. This treatment is currently undergoing a Phase 1 clinical trial. seekingalpha.com investorplace.com
NASDAQ:ARTL
by AlenCiken
$ARTL is gonna fall todayPupm&Dump trading strategy idea. $ARTL is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,15; stop-loss — $2,60; take-profit — $1,25; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ARTLShort
by KozakHlib
6
$ARTL is gonna fall todayPupm&Dump trading strategy idea. $ARTL is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $0,78; stop-loss — $0,96; take-profit — $0,60; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ARTLShort
by KozakHlib
1